首页 >
法规速递
-
Document: Minutes of the Cancer Medicines Forum - September 2025-2025/11/25
2025-11-26查看详情 > -
Document: QRD Appendix V - Adverse-drug-reaction reporting details-2025/12/17
2025-12-18查看详情 > -
Document: COMP work plan 2026-2026/2/2
2026-02-03查看详情 > -
Document: Record of data processing activity for EudraVigilance-2026/3/10
2026-03-11查看详情 > -
Page: Substances exempt from maximum residue limit evaluation-2026/4/8
2026-04-09查看详情 > -
国家药监局关于修订伊班膦酸钠注射液说明书的公告（2023年第2号）-2023/01/09
2023-01-09查看详情 > -
关于公开征求《糖尿病视网膜病变相关中药新药临床研发技术指导原则（征求意见稿）》意见的通知-2023/7/17
2023-07-21查看详情 > -
Page: Maximum residue limit (MRL) evaluation for biological substances - Scientific guideline-2024/1/26
2024-02-05查看详情 > -
Document: Procedural advice for orphan medicinal product designation: Guidance for sponsors-2025/1/30
2025-02-05查看详情 > -
Document: List of withdrawn medicinal products in accordance with Art. 123(4) of the Directive (1 January - 31 December 2024)-2025/3/7
2025-03-10查看详情 >
